Hair repigmentation during immunotherapy treatment with an anti–programmed cell death 1 and anti–programmed cell death ligand 1 agent for lung cancer

JAMA Dermatology

Volumn 153, Issue 11, 2017, Pages 1162-1165

  Rivera, Noelia ^a   Boada, Aram ^a   Bielsa, M Isabel ^a   Fernández Figueras, M Teresa ^b   Carcereny, Enric ^a   Moran, M Teresa ^a   Ferrándiz, Carlos ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CASE STUDY; CLINICAL ARTICLE; CLINICAL OBSERVATION; CUTANEOUS PARAMETERS; DESCRIPTIVE RESEARCH; FEMALE; FOLLOW UP; HAIR COLOR; HAIR REPIGMENTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPAIN; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DISEASE EXACERBATION; DRUG EFFECTS; IMMUNOTHERAPY; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; PROCEDURES; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HAIR COLOR; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 85032927129     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2017.2106     Document Type: Article

References (14)

1. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12-25.
2. Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol. 2015;38(4):422-430.
3. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908-918.
4. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13): 1270-1271.
5. Hwang SJE, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455-61.e1.
6. Tobin DJ. Aging of the hair follicle pigmentation system. Int J Trichology. 2009;1(2):83-93.
7. Lovering S, Miao W, Bailie T, Amato D. Hair repigmentation associated with thalidomide use for the treatment of multiple myeloma. BMJ Case Rep. 2016;2016:bcr2016215521.
8. Dasanu CA, Mitsis D, Alexandrescu DT. Hair repigmentation associated with the use of lenalidomide: graying may not be an irreversible process! J Oncol Pharm Pract. 2013;19(2):165-169.
9. Cheng YP, Chen HJ, Chiu HC. Erlotinib-induced hair repigmentation. Int J Dermatol. 2014;53(1):e55-e57.
10. Tintle SJ, Dabade TS, Kalish RA, Rosmarin DM. Repigmentation of hair following adalimumab therapy. Dermatol Online J. 2015;21(6): 13030/qt6fn0t1xz.
11. Nagase K, Inoue T, Narisawa Y. Manifest hair repigmentation associated with etretinate therapy. J Dermatol. 2017;44(3):e34-e35.
12. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti–PD-1 therapy. Eur J Cancer. 2016;60:190-209.
13. Arck PC, Overall R, Spatz K, et al. Towards a “free radical theory of graying”: melanocyte apoptosis in the aging human hair follicle is an indicator of oxidative stress induced tissue damage. FASEB J. 2006;20(9):1567-1569.
14. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.